Peru Supply Surge Narrative Masks Mission's Underlying Execution Risks

What happened

Zacks Investment Research published an article on March 17, 2026, portraying Mission Produce as capitalizing on Peru's avocado supply surge to drive sustainable growth through a volume-driven model. The DeepValue master report confirms Peru's role in Mission's vertical integration, with owned orchards boosting International Farming performance and supporting recent EBITDA improvements. However, the report highlights that such supply surges are inherently volatile, citing past weather-driven production shortfalls in Peru and persistent high capex that limits free cash flow. The article's optimistic framing overlooks critical risks detailed in filings, including tariff exposure, customer concentration, and integration challenges from the pending Calavo acquisition. Ultimately, while Mission benefits from Peru's supply, its long-term viability hinges on executing synergies and maintaining margins amid these structural headwinds.

Implication

The volume boost from Peru may temporarily lift earnings, but it fails to mitigate long-term margin pressures from tariffs and heavy capital expenditures. Mission's dependence on top customers for 67% of sales amplifies revenue volatility, especially if trade or pricing dynamics shift. Successful integration of the Calavo acquisition is crucial for synergy delivery, yet regulatory hurdles and execution missteps could derail pro forma EBITDA targets. Current valuation at ~8.3x EBITDA already prices in optimistic volume growth, offering limited margin of safety without tangible progress on cost savings. Therefore, waiting for a clearer entry point below $11 or evidence of Calavo approval and margin stability remains the prudent investment stance.

Thesis delta

The Zacks article underscores Mission's operational capability to harness supply surges, aligning with its volume-driven strategy, but it does not materially shift the investment thesis. DeepValue's 'WAIT' rating and cautious outlook remain valid, as upside is contingent on Calavo merger success and sustained EBITDA margins above 6%, not merely supply-driven volume gains. Investors should maintain a defensive position until regulatory clarity and synergy realization provide a more compelling risk-reward profile.